9 results about "Anticarcinogenic Effect" patented technology

This invention discloses the application of gluconate compounds in the preparation of drugs for the prevention and treatment of ovarian cancer. The gluconate compounds include at least one of sodium gluconate, potassium gluconate, calcium gluconate, and zinc gluconate. The invention also discloses the application of gluconate compounds in the preparation of inhibitors of the interaction between TMEM87A protein and CHP1 protein. This invention is the first to discover and demonstrate that gluconate compounds possess significant anti-ovarian cancer activity, effectively inhibiting the proliferation and metastasis of ovarian cancer cells. It also reveals for the first time a novel anti-cancer mechanism by which sodium gluconate directly binds to TMEM87A protein and disrupts the functional complex formed between TMEM87A and CHP1 protein. This invention overcomes the technical prejudice commonly held by those skilled in the art that gluconates are merely nutritional supplements or chelating agents, providing a novel, safe, and widely available class of candidate drugs for the treatment of ovarian cancer.

The present invention relates to an anticancer composition comprising *Jeonho* as an active ingredient. When using the composition, an anticancer composition capable of exhibiting an anticancer effect by inducing apoptosis of cancer cells and inhibiting cell proliferation or colony formation of cancer cells can be provided. By including the composition, an anticancer pharmaceutical composition and an anticancer functional food composition without the problem of side effects can be provided.

The invention describes peptides with anticancer activity and exhibiting antagonistic activity against CD133 protein, which were obtained and designed by means of computer tools, evaluating physicochemical parameters of flexibility, hydrophilicity, hydrophobicity, antigenicity and total charge as described herein, in addition to the modeling of the protein, which allowed selecting 4 regions with the appropriate characteristics. After modeling the selected peptides, CD133 peptide-protein molecular docking was performed, where stable interactions were observed, even showing hydrogen bonds. Finally, the peptides of the invention showed anticancer effects against several cancer cell lines, including cancer cells resistant to conventional treatments such as triple negative breast cancer cells.

The present invention relates to a pharmaceutical composition for inhibiting the resistance of liver cancer to sorafenib and enhancing an anticancer effect, comprising an Estrogen-related receptor γ (ERRγ) inhibitor as an active ingredient. The present invention can be effectively used as a pharmaceutical composition for treating sorafenib-resistant advanced liver cancer.

The present disclosure relates to methods of treating patients having liver cancer by performing a genome-targeting technique. It is based, at least in part, on the discovery that a genome editing technique that specifically targets genomic mutations can induce cell death in a cancer cell, e.g., a hepatocellular cancer cell, having the genomic gene. The present disclosure provides methods for treating cancer patients that include performing a genome editing technique targeting a genomic mutation present within one or more cells of a subject to produce an anti-cancer effect.

Provided is a cancer-associated fibroblast inhibitor, particularly a cancer-associated fibroblast inhibitor capable of enhancing the anticancer effect of an anticancer agent. A cancer-associated fibroblast inhibitor containing a PDGFR inhibitor.

This invention belongs to the field of pharmaceutical technology and discloses the inhibitory effects and mechanisms of action of sclerotinib on lung cancer cells, cervical cancer cells, and ovarian cancer cells. Compared with the currently available broad-spectrum antitumor drug fluorouracil, sclerotinib exhibits superior antitumor properties. In-depth research revealed that sclerotinib acts on the novel protein STAT3 in cancer treatment, inhibiting STAT3 phosphorylation and preventing phosphonate-modified protein dimers from entering the cell nucleus to initiate transcription. Furthermore, sclerotinib inhibits the downstream anti-apoptotic protein BCL-2 of STAT3, synergistically inhibiting tumor cell proliferation. In this study, based on the half-maximal inhibitory concentration (IC50) results of sclerotinib against lung cancer cells A549, cervical cancer cells HeLa, and ovarian cancer cells A2780, we directly verified the anticancer target of sclerotinib through experiments, elucidated its anticancer mechanism, and provided theoretical and experimental basis for its entry into preclinical and clinical trials.

The present invention relates to the compound of formula (1a) wherein a-d and p are 1 or 2, R1-R4 are hydrogen atom or the like, and R18 is —CF3 or the like, or a pharmaceutically acceptable salt thereof, which has an anticancer effect by inhibiting the binding between a MLL fusion protein that is fused with AF4, AF9, or the like, which is a representative fusion partner gene causing MLL leukemia, and menin.